BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Pharma & GLP-1
EASO's 2026 Living Algorithm Separates Tirzepatide and Semaglutide by Indication — With MASH Data Sharpening the Divide
The European Association for the Study of Obesity has published its first update to its GLP-1 pharmacotherapy framework, drawing a clearer evidence-based distinction between tirzepatide and semaglutide. Tirzepatide now sits above semaglutide for total body weight loss, while semaglutide is the only agent currently supported for liver fibrosis improvement — a split with direct implications for research strategy as Novo Nordisk advances its MASH programme into EASL 2026.
21 May 2026
Pharma & GLP-1
Wegovy oral pill claims early US lead over Lilly's Foundayo as Novo Nordisk Q1 results approach
Novo Nordisk's oral semaglutide pill (FDA-approved December 2025) and Eli Lilly's orforglipron (Foundayo, approved 1 April 2026) are now competing head-to-head in the US oral GLP-1 market. Cross-trial data favours Wegovy on weight loss; Foundayo has a usability edge. UK launch timing is unclear pending MHRA review.
05 May 2026